Amryt

Amryt

Develops and delivers treatments for patients with rare and orphan diseases.. Learn more

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD20172018201920202021
Revenues15.3m17.1m58.1m183m223m
% growth-12 %240 %214 %22 %
EBITDA(30.0m)(28.5m)(42.7m)(39.1m)67.6m
% EBITDA margin(196 %)(167 %)(74 %)(21 %)30 %
Profit(31.4m)(30.5m)(63.0m)(105m)1.0m
% profit margin(205 %)(178 %)(108 %)(57 %)-
R&D budget12.7m10.7m15.8m27.6m37.7m
R&D % of revenue83 %63 %27 %15 %17 %
  • Edit
DateInvestorsAmountRound

$9.0m

Late VC
N/A

N/A

IPO
N/A

€2.0m

Post IPO Equity
N/A

€20.0m

Post IPO Debt
N/A

€33.0m

Valuation: €350m

6.6x EV/LTM Revenues

-9.0x EV/LTM EBITDA

Private Placement VC
*

$125m

Post IPO Debt
*

$1.3b

Valuation: $1.3b

Acquisition
Total Funding€41.2m

Recent News about Amryt

Edit
More about Amrytinfo icon
Edit

Amryt Pharma Plc is a commercial-stage pharmaceutical company dedicated to developing and delivering innovative treatments for rare and orphan diseases. The company focuses on providing solutions that significantly improve the lives of patients who suffer from these challenging conditions. Amryt Pharma operates in the global pharmaceutical market, serving healthcare professionals who treat complex and rare diseases. The business model is centered around the research, development, and commercialization of novel therapies. Revenue is generated through the sale of these specialized medicines and through strategic partnerships with other pharmaceutical companies. Amryt Pharma prides itself on its nimble and creative approach to business development, ensuring mutual benefits in all partnerships.

Keywords: rare diseases, orphan diseases, pharmaceutical, innovative treatments, healthcare professionals, global market, business development, strategic partnerships, commercialization, novel therapies.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Amryt

Edit
Chiasma
ACQUISITION by Amryt May 2021
Aegerion Pharmaceuticals
ACQUISITION by Amryt Jun 2019
Sompharmaceuticals
ACQUISITION by Amryt May 2016